WPI, Watson Pharmaceuticals, Inc.
** WPI reported that it has launched a generic version of Actos(NYSE:R) (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after receiving final approval from the FDA. WPI began shipping the product immediately.
According to IMS Health data, for the 12 months ending August 31, 2012, Actos(R) and its generic equivalents had total U.S. sales of approximately $2.7 billion.
Pioglitazone is used with a diet and exercise program and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Pioglitazone is in a class of medications called thiazolidinediones. It works by increasing the body's sensitivity to insulin, a natural substance that helps control blood sugar levels.
Pioglitazone is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated).
WPI is an integrated global specialty pharmaceutical company. WPI is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.
More about WPI at www.watson.com.
Read Full Disclaimer at http://CRWENews.com/disclaimer
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.